A phase I, ascending dose, to evaluate safety and efficacy of ADP A2M4CD8 in HLA-A2+ patients with MAGE-A4 psoitives tumors

×

Error message

  • Notice: Trying to access array offset on value of type null in bootstrap_pager() (line 53 of /var/www/biosafety.be/sites/all/themes/bootstrap/templates/system/pager.func.php).
  • Notice: Trying to access array offset on value of type null in bootstrap_pager() (line 95 of /var/www/biosafety.be/sites/all/themes/bootstrap/templates/system/pager.func.php).
Study title: 
A phase I, ascending dose, to evaluate safety and efficacy of ADP A2M4CD8 in HLA-A2+ patients with MAGE-A4 psoitives tumors
Long title: 
A phase I, ascending dose, to evaluate safety and efficacy of ADP A2M4CD8 in HLA-A2+ patients with MAGE-A4 psoitives tumors
Date receipt dossier: 
11 Oct 2019
EU record number: 
ADP-0055-001
EudraCT number: 
2019-001965-34
Pharmaceutical study code: 
A2M4CD8
Company / Sponsor: 
Adaptimmune LLC
Phase: 
I
Treated organism: 
Humans
Indication category: 
Cancer therapy
Disease: 
MAGE-A4 positive tumors
Therapeutic approach: 
Immunotherapy
Genetic modification: 
MAGE-A4 specific T cell receptor (TCR) with a CD8α co-receptor
Method of transfer of nucleic acid of interest: 
Lentiviral vectors
Administered biological material: 
Autologous T cells transduced with lentiviral vectors expressing a MAGE-A4 specific T cell receptor (TCR) with a CD8α co-receptor.
Route of administration: 
Intravenous
Locations in Belgium: 
Cliniques Universitaires Saint-Luc; UZ Antwerpen; U Gent
Type of procedure: 
Contained use only
Current status: 
Authorized